ArticleExploratory research in clinical and social pharmacy2025
Adherence to oral anticancer medications in metastatic versus nonmetastatic breast cancer patients: Insights from a low-middle-income country.
Article in Exploratory research in clinical and social pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medication adherence in breast cancer: a comparative analysis of self-report tools and prescription refill data.European journal of clinical pharmacology · 2026Trial
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimal treatment outcomes in breast cancer rely heavily on patient adherence to oral anticancer medications (OAMs). Aim: This study aimed to assess adherence to OAMs and identify factors associated with nonadherence in metastatic and nonmetastatic breast cancer patients. Methods: In this cross-sectional study at the National Cancer Institute, Cairo University, 500 breast cancer patients were categorised into metastatic (45.6 %) and nonmetastatic (54.4 %) groups. Adherence was measured using the Morisky Medication Adherence Scale (MMAS-8) and the Medication Possession Ratio (MPR), with nonadherence defined as an MMAS-8 score < 8 or an MPR < 80 %. Data collection was augmented by patient interviews and examinations of outpatient pharmacy dispensing records. Results: Adherence rates were 46.4 % as per MMAS-8 and 71 % according to MPR. Specifically, in the nonmetastatic group, MMAS-8 revealed a 28.3 % adherence rate, MPR showed 75.4 % adherence rate. Metastatic patients displayed significantly higher adherence (MASS-8, 68 %) ( Conclusion: This study confirms that adherence to OAMs is significantly affected by both the metastatic status and the severity of side effects. This highlights the urgent need for enhanced educational and management strategies tailored to the specific challenges faced by breast cancer patients, especially those dealing with severe side effects. Ongoing research should focus on developing and testing targeted interventions to improve adherence in these patient groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.